Small molecular weight protein-protein interaction antagonists: an insurmountable challenge?

[1]  D A Scudiero,et al.  Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. , 1989, Journal of the National Cancer Institute.

[2]  T. Clackson,et al.  A hot spot of binding energy in a hormone-receptor interface , 1995, Science.

[3]  A. Levine,et al.  Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain , 1996, Science.

[4]  A. Jochemsen,et al.  MDMX: a novel p53‐binding protein with some functional properties of MDM2. , 1996, The EMBO journal.

[5]  C. Renner,et al.  Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. , 2001, Biochemistry.

[6]  Min Wu,et al.  The initial evaluation of non-peptidic small-molecule HDM2 inhibitors based on p53-HDM2 complex structure. , 2002, Cancer letters.

[7]  J. Thornton,et al.  Diversity of protein–protein interactions , 2003, The EMBO journal.

[8]  N. Davidson,et al.  Design, synthesis, and evaluation of novel boronic-chalcone derivatives as antitumor agents. , 2003, Journal of Medicinal Chemistry.

[9]  David C Fry,et al.  NMR structure of a complex between MDM2 and a small molecule inhibitor , 2004, Journal of biomolecular NMR.

[10]  M. Protopopova,et al.  Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors , 2004, Nature Medicine.

[11]  Donald J Abraham,et al.  A nonpeptidic sulfonamide inhibits the p53-mdm2 interaction and activates p53-dependent transcription in mdm2-overexpressing cells. , 2004, Journal of medicinal chemistry.

[12]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[13]  Mahavir Singh,et al.  Monitoring the effects of antagonists on protein-protein interactions with NMR spectroscopy. , 2005, Journal of the American Chemical Society.

[14]  Per Källblad,et al.  Isoindolinone-based inhibitors of the MDM2-p53 protein-protein interaction. , 2005, Bioorganic & medicinal chemistry letters.

[15]  S. Sebti,et al.  Terphenyl-based helical mimetics that disrupt the p53/HDM2 interaction. , 2005, Angewandte Chemie.

[16]  Maxwell D Cummings,et al.  Structure-based design, synthesis, and biological evaluation of novel 1,4-diazepines as HDM2 antagonists. , 2005, Bioorganic & medicinal chemistry letters.

[17]  Maxwell D Cummings,et al.  Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. , 2005, Journal of medicinal chemistry.

[18]  T. Holak,et al.  NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro , 2005, Nature Medicine.

[19]  Do-Hyoung Kim,et al.  Structural Details on mdm2-p53 Interaction* , 2005, Journal of Biological Chemistry.

[20]  Maxwell D Cummings,et al.  Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2-p53 protein-protein interaction through structure-based drug design. , 2006, Bioorganic & medicinal chemistry letters.

[21]  S. Francoz,et al.  Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[22]  H. Yokosawa,et al.  Hexylitaconic acid: a new inhibitor of p53-HDM2 interaction isolated from a marine-derived fungus, Arthrinium sp. , 2006, Bioorganic & medicinal chemistry letters.

[23]  Maxwell D Cummings,et al.  Substituted 1,4‐Benzodiazepine‐2,5‐diones as α‐Helix Mimetic Antagonists of the HDM2‐p53 Protein–Protein Interaction , 2006, Chemical biology & drug design.

[24]  Xueliang Fang,et al.  Discovery of a nanomolar inhibitor of the human murine double minute 2 (MDM2)-p53 interaction through an integrated, virtual database screening strategy. , 2006, Journal of medicinal chemistry.

[25]  Geng-Hung Liu,et al.  Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[26]  N. Davidson,et al.  Anticancer activities of novel chalcone and bis-chalcone derivatives. , 2006, Bioorganic & medicinal chemistry.

[27]  Gerard I. Evan,et al.  Modeling the Therapeutic Efficacy of p53 Restoration in Tumors , 2006, Cell.

[28]  Do-Hyoung Kim,et al.  Proteomimetic libraries: design, synthesis, and evaluation of p53-MDM2 interaction inhibitors. , 2006, Journal of combinatorial chemistry.

[29]  D. Parks,et al.  Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo , 2006, Molecular Cancer Therapeutics.

[30]  Su Qiu,et al.  Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. , 2006, Journal of medicinal chemistry.

[31]  T. Holak,et al.  Molecular Basis for the Inhibition of p53 by Mdmx , 2007, Cell cycle.

[32]  T. Jacks,et al.  Restoration of p53 function leads to tumour regression in vivo , 2007, Nature.

[33]  L. Vassilev,et al.  MDM2 inhibitors for cancer therapy. , 2007, Trends in molecular medicine.

[34]  L. Vassilev,et al.  Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1 , 2007, Oncogene.

[35]  Heather A Carlson,et al.  Small molecule inhibitors of the MDM2-p53 interaction discovered by ensemble-based receptor models. , 2007, Journal of the American Chemical Society.

[36]  Brian D. Marsden,et al.  The scientific impact of the Structural Genomics Consortium: a protein family and ligand-centered approach to medically-relevant human proteins , 2007, Journal of Structural and Functional Genomics.

[37]  R. Goodnow,et al.  Exploration of liquid and supercritical fluid chromatographic chiral separation and purification of Nutlin-3--a small molecule antagonist of MDM2. , 2007, Journal of pharmaceutical and biomedical analysis.

[38]  L. Mayo,et al.  Nutlin3 blocks vascular endothelial growth factor induction by preventing the interaction between hypoxia inducible factor 1alpha and Hdm2. , 2007, Cancer research.

[39]  Carlos Cordon-Cardo,et al.  Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas , 2007, Nature.

[40]  S. Gellman,et al.  Targeting protein-protein interactions: lessons from p53/MDM2. , 2007, Biopolymers.

[41]  Michael A. Dyer,et al.  MDMX: from bench to bedside , 2007, Journal of Cell Science.

[42]  D. Lane,et al.  Updates on p53: modulation of p53 degradation as a therapeutic approach , 2008, British Journal of Cancer.

[43]  Dajun Yang,et al.  Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition , 2008, Proceedings of the National Academy of Sciences.